Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NOUS 209

Next Previous
Drug Profile

NOUS 209

Alternative Names: GAd20-209-FSP; MVA-209-FSP; NOUS-209

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nouscom
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hereditary nonpolyposis colorectal cancer; Solid tumours

Most Recent Events

  • 13 Oct 2025 Nouscom plans Type B and C meetings with the US FDA for Hereditary nonpolyposis colorectal cancer
  • 13 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours released by Nouscom
  • 13 Oct 2025 Nouscom completes a phase I/II trial in Solid tumours (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA, Belgium, Canada, Italy, Spain, and United Kingdom (IM)(NCT04041310)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top